# Unpredictability of the fitness effects of antimicrobial resistance mutations across 1 environments in Escherichia coli 2 Aaron Hinz<sup>1,2,3\*</sup>, André Amado<sup>4,5,6</sup>, Rees Kassen<sup>2,3</sup>, Claudia Bank<sup>4,5,6</sup>, Alex Wong<sup>1</sup> <sup>1</sup> Department of Biology, Carleton University, Ottawa, ON K1S 5B6, Canada <sup>2</sup> Department of Biology, University of Ottawa, Ottawa, ON K1N 6N5, Canada <sup>3</sup> Department of Biology, McGill University, Montreal, QC H3A 1B1, Canada <sup>4</sup> Institute of Ecology and Evolution, University of Bern, Switzerland <sup>5</sup> Swiss Institute of Bioinformatics, Lausanne, Switzerland <sup>6</sup> Gulbenkian Science Institute, Oeiras, Portugal \* Corresponding author Email: aaron.hinz@mcgill.ca (AH) Keywords: Antimicrobial Resistance, Costs of Resistance, Genotype-by-Environment Interactions, Epistasis, Fitness Landscapes, Rough Mount Fuji Model

© The Author(s) 2024. Published by Oxford University Press on behalf of Society for Molecular Biology and Evolution. This is an Open Access article distributed under the terms of the Creative Commons Attribution -NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com.

# 1 Abstract

The evolution of antimicrobial resistance (AMR) in bacteria is a major public health 2 concern, and antibiotic restriction is often implemented to reduce the spread of resistance. These 3 measures rely on the existence of deleterious fitness effects (i.e., costs) imposed by AMR 4 mutations during growth in the absence of antibiotics. According to this assumption, resistant 5 6 strains will be outcompeted by susceptible strains that do not pay the cost during the period of restriction. The fitness effects of AMR mutations are generally studied in laboratory reference 7 strains grown in standard growth environments; however, the genetic and environmental context 8 can influence the magnitude and direction of a mutation's fitness effects. In this study, we 9 measure how three sources of variation impact the fitness effects of Escherichia coli AMR 10 mutations: the type of resistance mutation, the genetic background of the host, and the growth 11 environment. We demonstrate that while AMR mutations are generally costly in antibiotic-free 12 environments, their fitness effects vary widely and depend on complex interactions between the 13 mutation, genetic background, and environment. We test the ability of the Rough Mount Fuji 14 fitness landscape model to reproduce the empirical data in simulation. We identify model 15 parameters that reasonably capture the variation in fitness effects due to genetic variation. 16 17 However, the model fails to accommodate the observed variation when considering multiple growth environments. Overall, this study reveals a wealth of variation in the fitness effects of 18 19 resistance mutations owing to genetic background and environmental conditions, that will ultimately impact their persistence in natural populations. 20

# 1 Introduction

2

3	Pervasive antibiotic use selects for bacteria with antimicrobial resistance (AMR) and has
4	led to rising prevalence of multidrug-resistant pathogens (World Health Organization 2015;
5	Holmes et al. 2016; Council of Canadian Academies 2019; CDC 2020). Considering the slow
6	pace of antibiotic discovery (Jackson et al. 2018), effective stewardship of existing antibiotics is
7	essential. Antibiotic restriction is a widely used approach that aims to reverse the spread of
8	resistance by reducing the selective pressure that maintains AMR in bacterial populations.
9	Antibiotic restriction was observed to correlate with decreased resistance in medical,
10	agricultural, and veterinary settings, although responses vary widely, with resistance rarely
11	eliminated, and some efforts failing entirely (Enne 2010; Dierikx et al. 2016; Pitiriga et al. 2017;
12	Tang et al. 2017; Veldman and Mevius 2018). The ability to predict success or failure of
13	antibiotic restriction will be important for implementing more rational interventions.
14	The premise behind antibiotic restriction is that resistant microbes are outcompeted by
15	susceptible microbes in antibiotic-free environments due to fitness costs imposed by resistance
16	determinants. These costs can derive from functional tradeoffs of altering antibiotic targets,
17	unregulated expression of drug efflux pumps, or burdens of maintaining replicating resistance
18	plasmids (Durão et al. 2018). However, while evidence indicates that AMR mutations are
19	generally costly (Melnyk et al. 2015), several mechanisms can promote AMR persistence even in
20	the absence of direct antibiotic selection. First, resistance to a restricted antibiotic can be
21	indirectly selected by the presence of non-restricted antibiotics via mechanisms of cross-
22	resistance (Alekshun and Levy 1999; Bhardwaj et al. 2017; Brown et al. 2019) or co-selection of
23	genetically linked resistance determinants (Enne et al. 2001; Sundqvist et al. 2010; Hughes and

.

1 Andersson 2017). Second, some AMR mutations may incur little or no cost to the microbe,

2 allowing resistance to be maintained in antibiotic-free environments (Melnyk et al. 2017). Third,

3 costs might be heterogeneous across different environments, allowing for resistance to be

4 maintained in cost-free environmental refuges (Leale and Kassen 2018). Finally, second-site

5 compensatory mutations, either segregating in the population or arising after resistance

6 evolution, can reduce fitness costs without loss of resistance (Durão et al. 2018).

Knowledge of the range of fitness effects caused by AMR mutations is crucial to guide 7 decision-making but comprehensive data are lacking. Standard practice is to obtain experimental 8 measures of the fitness effects of AMR mutations from well-characterized laboratory strains 9 grown in standard growth media (Melnyk et al. 2015; Vogwill and MacLean 2015); however, it 10 has become increasingly evident that these fitness effects can be modulated by both genetic and 11 environmental variation (Hall 2013; Vogwill et al. 2016; Wong 2017; Clarke et al. 2020). For 12 example, the magnitude or the direction (costly vs. beneficial) of a mutation's fitness effect may 13 14 change depending on the genetic background in which the mutation evolved, a form of genotype by genotype (G x G) interaction known as epistasis (Trindade et al. 2009; Vogwill et al. 2016; 15 Wong 2017). The growth environment can also impact fitness effects in ways that are hard to 16 anticipate, a form of genotype by environment (G x E) interaction (Hall 2013; Maharjan and 17 Ferenci 2017). Furthermore, higher-order interactions between the nature of the AMR mutation 18 19 itself (modification of a target site versus deregulation of an efflux pump, for example), the 20 genetic background on which the mutation occurs, and the growth environment (G x G x E interactions) can further complicate matters, potentially undermining predictions based on data 21 22 from single genotypes and environments (Flynn et al. 2013; Hall 2013; Ghenu et al. 2023). 23 Currently we know very little about the extent to which the fitness effects of AMR mutations are

consistent or variable across genotypes and environments. Obtaining such data is an important 1 step towards predicting the success of antibiotic restriction strategies. 2

Ultimately, it will never be possible to empirically measure fitness for every mutation-3 genotype combination in all environments a microbial strain could encounter. Theoretical 4 modeling could offer a complementary approach to predict the fitness of microorganisms across 5 the various environments they populate. Two different types of models provide a rough 6 prediction of antibiotic resistance fitness landscapes. Hill curve models predict fitness across 7 8 antibiotic gradients but disregard other sources of environmental variation (Das et al. 2020). Alternatively, approaches based on Fisher's Geometric Model tend to have more general 9 applicability, but have many parameters, require extensive datasets, and are in practice 10 11 cumbersome to fit (Blanquart et al. 2014; Blanquart and Bataillon 2016; Harmand et al. 2017). Probabilistic fitness landscape models, such as the Rough Mount Fuji (RMF) model (Aita et al. 12 2000), are a third type of model that capture the relationship between genotype and fitness. 13 14 These models are appealing because they feature tunable epistasis and are determined by few parameters (Bank 2022). In addition, they reasonably approximate some experimental fitness 15 landscapes (e.g., Bank et al. 2016). 16

In this study, we present an empirical analysis of genetic and environmental factors that 17 contribute to the variation in fitness effects among resistance mutations in Escherichia coli and 18 19 evaluate the performance of an RMF-based genotype-fitness model to reproduce the empirical 20 results. We introduced 7 resistance mutations individually into each of 12, primarily clinical, strains and quantified each resistance mutation's fitness effect in four distinct growth 21 22 environments. Overall, we show that fitness effects are extensively modulated by all three 23 sources of variation: the type of AMR mutation, the genetic background, and the growth

environment. The RMF model reproduced single-environment empirical results well but was
unable to recover their full complexity when all environments were considered together. Our
study highlights the challenges of predicting fitness effects from empirical data obtained from
limited genetic backgrounds and environments while at the same time calling for improved

- 5 fitness landscape models that account for these important sources of variation.
- 6
- 7 **Results**
- 8

# 9 Library of *E. coli* clinical isolates with introduced resistance

#### 10 mutations

11

We constructed a factorial mutant library by introducing each of 7 antimicrobial 12 resistance mutations into 12 E. coli isolates using oligonucleotide-mediated mutagenesis (Lennen 13 et al. 2016). The total number of mutant constructs was 67, after accounting for failed 14 constructions and isolates that were resistant to the respective antibiotic or already harbored the 15 mutation (fig. 1). The genetic backgrounds sampled were the laboratory strain MG1655 and 11 16 clinical isolates, including enterohemorrhagic (EHEC) and extraintestinal pathogenic (ExPEC) 17 *E. coli*, that vary in serotype, antibiotic resistance profile, and plasmid presence (Basra et al. 18 19 2018; McCarthy 2020). For generalizability, we selected mutations that confer resistance to multiple antibiotic classes (fluoroquinolone, rifampicin, aminoglycoside) by modifying drug 20 21 binding sites or by upregulating antibiotic efflux (Alekshun and Levy 1999; Nakamura et al. 22 1989; Vila et al. 1994; Morgan-Linnell et al. 2009). Fitness effects of mutations in gyrA, rpoB,

11	coli genetic backgrounds
10	Mutations cause similar increases in antibiotic resistance across E.
9	
8	sample the genomic diversity of pathogenic E. coli populations found in nature.
7	mutations causing resistance to multiple antibiotic types introduced in genetic backgrounds that
6	al. 2017; Bhatnagar and Wong 2019). Overall, the mutant library includes a range of AMR
5	et al. 1996; Hopkins et al. 2005; Lee et al. 2005; Goldstein 2014; Melnyk et al. 2015; Huseby et
4	Pseudomonas aeruginosa and Mycobacterium tuberculosis (gyrA, gyrB, rpoB, rpsL) (Sreevatsan
3	genes contribute to clinical resistance in E. coli (gyrA, marR) and other pathogens such as
2	Trindade et al. 2012; Durão et al. 2015), but not in clinical isolates. Mutations in the selected
1	and <i>rpsL</i> have been extensively characterized in <i>E. coli</i> reference strains (Trindade et al. 2009;

- coli genetic backgrounds 11
- 12

We expected the mutants to exhibit increased resistance to antibiotics whose inhibitory 13 action or efflux was directly impacted by the introduced mutation. However, indirect effects of 14 the mutations against non-target antibiotics (i.e., cross-resistance or collateral sensitivity), and 15 the extent to which antibiotic susceptibilities depended on the genetic background were 16 unknown. We therefore performed minimum inhibitory concentration (MIC) assays to quantify 17 18 fold-changes in susceptibility to both target and non-target antibiotics (fig. 2). We found that the 19 introduced mutations significantly increased resistance to target antibiotics across the genetic 20 backgrounds. Thus, fluoroquinolone resistance mutations (in gyrA, gyrB, and marR) increased 21 ciprofloxacin resistance, rpoB mutations increased rifampicin resistance, and rpsL mutations 22 increased streptomycin resistance. Although several instances of collateral sensitivity were 23 observed, none were significant when considering all genetic backgrounds.

1	There was little variation in the fold increases in antibiotic resistance for mutants sharing
2	the same mutation but differing in genetic background. In a mixed effect linear model,
3	knowledge of the identity of the mutation explained 89% of the fold change variance, with
4	random effects of genetic background contributing only 9.7% of the explained variance.
5	Moreover, some of the variation in MIC fold increase to the target antibiotics could be explained
6	by differences in the initial resistance of the ancestral isolates. For one mutation (RpoB
7	(H526Y)), there was a negative correlation between fold increase in rifampicin MIC and the
8	initial resistance of the ancestor (supplementary fig. S1). This result is suggestive of 'diminishing
9	returns' epistasis, where mutations confer smaller beneficial effects in more fit genotypes (Diaz-
10	Colunga et al. 2023), although the generally low MIC variation among the isolates prevented a
11	robust test of this phenomenon. In conclusion, analysis of the antibiotic susceptibilities found
12	that the introduced AMR mutations predictably increased AMR to target antibiotics across
13	genetic backgrounds with few collateral effects against non-target antibiotics.
14	

# 15 Fitness effects of mutations vary widely across genetic backgrounds

16

We next investigated whether the consistent increases in antibiotic resistance caused by the mutations were also reflected in predictable competitive fitness effects in antibiotic-free environments. Though AMR mutations are generally expected to be costly, fitness effects could vary depending on the identity of the mutation, genetic background, or growth environment. We measured fitness effects in head-to-head competition assays in four discrete antibiotic-free growth environments: rich (LB) and minimal (M9-Glucose) laboratory media, and two media that simulate urinary tract and colon environments colonized by pathogenic *E. coli* (Laube et al. 2001; Polzin et al. 2013). The growth yields of the environments varied, with an over 10-fold
change in carrying capacity between the highest yield (LB) and lowest yield (synthetic urine)
media (supplementary fig. S2). Fitness effects were estimated by calculating the fitness of each
mutant relative to its unmutated ancestor, thus allowing for comparisons between mutants
generated from different genetic backgrounds.

The fitness effects of the studied AMR mutations are summarized in fig. 3, where 6 individual points in each boxplot represent different genetic backgrounds sharing the same 7 8 mutation. The mutations were generally costly (with relative fitness < 1); however, there was wide variation in the fitness effects across genetic backgrounds including neutral and, 9 surprisingly, even beneficial effects. This variation contrasts with the antibiotic susceptibility 10 phenotypes, which varied little across genetic backgrounds (fig. 2). The dependence of the 11 fitness effects on the genetic background is evidence of epistasis between AMR mutations and 12 genetic backgrounds, a type of G X G interaction. 13

We summarized the fitness effects for all combinations of the focal mutations and genetic 14 backgrounds in each environment with three statistics: (1) the mean fitness effects across 15 mutations and genetic backgrounds; (2) the overall variance in fitness effects; and (3) the amount 16 of epistasis between mutations and genetic backgrounds (fig. 4). Epistasis was estimated using 17 the summary statistic gamma ( $\gamma$ ), defined as the correlation of fitness effects of the set of AMR 18 19 mutations across multiple genetic backgrounds (Ferretti et al. 2016). We found that despite 20 similar mean fitness effects (between -0.06 and -0.092), the variance of the fitness effects and amount of epistasis varied considerably depending on the growth environment. Fitness effect 21 22 variance was much larger in the media mimicking the infection environments (synthetic urine 23 and synthetic colon media), whereas epistasis was stronger (i.e., there was a lower correlation of

fitness effects across genetic backgrounds) for synthetic urine and M9-Glucose media, compared 1 to synthetic colon and LB media. Despite differences in the total strength of epistasis, the four 2 environments exhibited roughly similar proportions of epistasis types (supplementary fig. S4), 3 with ~60-70% classified as magnitude epistasis, in which the genetic background affects fitness 4 non-additively in the same direction, and  $\sim$ 30-40% as sign epistasis, in which the genetic 5 background affects the direction of the fitness effect (e.g., deleterious to beneficial or vice versa). 6 Taken together, our results demonstrate the important role of epistasis in determining fitness 7 effects of AMR mutations and, furthermore, the influence of the growth environment on both the 8 overall variation in fitness effects and strength of epistasis between mutations and genetic 9 backgrounds. 10

11

# 12 Variation in fitness effects is governed by irreducible G x E

#### 13 interactions

14

The experimental fitness data highlight the dramatic influence of the growth environment 15 on the fitness effects of AMR mutations. Changing the growth environment can lead to 16 differences in fitness that depend on both the identity of the mutation and the genetic background 17 (fig. 3). For example, the gyrB mutation was highly costly in synthetic colon medium but less 18 19 costly (and sometimes beneficial) in synthetic urine medium. The gyrA and marR mutations, on 20 the other hand, exhibited the opposite response in these two environments. These results 21 demonstrate that the impact of growth environments on fitness can vary from mutation to 22 mutation (i.e., mutation by environment interaction).

1	The genetic background also played a major role in determining fitness effects across
2	environments. Reaction norm plots of the fitness effects (supplementary fig. S5) indicate that
3	differences in a mutation's fitness effect caused by shifting the growth environment depended on
4	the genetic background, which impacts both the magnitude and direction (i.e., beneficial vs.
5	deleterious) of the fitness effect. G x E interactions are also illustrated by the idiosyncratic
6	genetic backgrounds that frequently yielded outlier fitness values depending on the introduced
7	mutation and environment (e.g., strains OLC682 and PB1). Overall, our results clearly illustrate
8	that the fitness effects of the AMR mutations we sampled are influenced by complex interactions
9	between AMR mutations, genetic backgrounds, and growth environment.
10	We next leveraged the factorial design of the experiment to quantify the importance of
11	genetic background by environment (G x E) interactions in explaining the variation of fitness
12	effects in the experimental data. We quantified the variance contributed by genetic background
13	and environment in a linear mixed effect model treating genetic background, environment, and
14	their interaction as random factors. We found that for each of the mutations, over 50% of the
15	variation in fitness was explained by the interaction between genetic background and
16	environment (fig. 5). Although the main effect of environment explained a portion (up to 17%)
17	of the variation for several mutations, in general, the effect of environment on a mutation's
18	fitness effects strongly depended on its genetic background. In other words, neither knowledge
19	of the growth environment nor of the identity of the genetic background were by themselves
20	sufficient to predict fitness effects of each of the mutations.
21	

# The complex G x G x E interactions in the experimental data are not captured by a probabilistic fitness landscape model

3

Our dataset provides a powerful test case for investigating the predictability of mutational 4 fitness effects. For example, given data from one environment, can we predict the fitness effects 5 of AMR mutations in a second environment? In the previous section we showed that the data 6 exhibit strong variation in fitness effects and epistasis within and between environments, 7 indicating ubiquitous G x G and G x E interactions (figs. 4 and 5). Would such variation be 8 expected under a simple fitness landscape model, and would the data be consistent with the same 9 fitness landscape being sampled independently for each of the environments? If yes, this 10 indicates that at least statistical properties of the data (such as the variance in fitness effects and 11 epistasis) are predictable, even in the absence of detailed mechanistic knowledge of the cellular 12 and physiological effects. We chose the Rough-Mount-Fuji (RMF) model (Aita et al. 2000) to 13 address this question due to its success in describing single environment fitness landscapes and 14 its reliance on few parameters (Szendro et al. 2013; Bank et al. 2016). The model considers a 15 16 genotype as a set of alleles at diallelic loci, which each contribute additively to fitness, plus a 17 random epistatic component, specific to each genotype, which also contributes to fitness. The model can be tuned from completely additive to completely epistatic by adjusting the 18 distributions from which the additive and epistatic components of fitness are drawn. 19

To test whether the experimental data were consistent with an underlying RMF fitness landscape, we simulated a total of 100,000 fitness landscapes with 7 diallelic loci on 12 different genetic backgrounds (i.e., 84 genotypes) for 10,000 sets of model parameters ( $\sigma_a$  and  $\sigma_b$ ),

1	encompassing a total of $10^9$ simulated fitness landscapes (see Methods section for details). We
2	then computed the three fitness statistics (fig. 4; mean fitness, fitness variance, and gamma
3	epistasis) of the sampled data. We first computed which set of model parameters could best
4	reproduce the fitness statistics observed in the experimental data for each environment
5	separately, and how well this best model fits the data. Each statistic of the experimental data was
6	then computed under the RMF model with the given parameters. Fig. 6A shows a projection of
7	the log-likelihood of each statistic, where the other dimensions are fixed for the parameters that
8	provide the overall best fit. For LB and M9-Glucose environments, we found similar RMF model
9	parameters as best fits for the experimental fitness statistics. The parameters that described
10	synthetic urine and synthetic colon media best were very different from the other two
11	environments, requiring a much larger variance in the epistatic component of the model for both
12	environments, and a larger variance in the additive component in the case of synthetic urine
13	medium. This discrepancy made it difficult to find shared model parameters to characterize the
14	entire dataset.
15	We next tested how well the model could capture the four different environments

16 simultaneously. In other words, could the fitness effects of genotypes across different environments be explained by independent samples of the same underlying RMF landscape? 17 18 Notably, the model failed entirely to accommodate the multi-environment data. Fig. 6B 19 illustrates the tradeoff that occurs when optimizing the parameter space for fitness variance vs 20 epistasis by overlaying the model-generated fitness statistics (grey probability distributions) with 21 the experimental values obtained for each environment (vertical lines). The results demonstrate 22 that when optimized for fitness variance, the model completely fails to produce the epistasis 23 values associated with any of the four environments in the experimental data. Conversely,

optimizing the model for epistasis fails to capture the fitness variance. Thus, no single set of RMF parameters could adequately capture key features of the data across all environments.

3

2

#### 4 Fitness effects weakly correlate across pairs of environments

5

6 The complex G x G and G x E interactions observed in the experimental data, as well as the inability of the RMF model to accommodate the multi-environment dataset indicate that 7 fitness effects measured in one environment do not necessarily translate to alternative 8 environments. To directly ask whether fitness data from one environment can be used to predict 9 fitness in another environment, we calculated the correlations of fitness effects between pairs of 10 environments. Grouping all mutations together (fig. 7A), we found that, in general, fitness effects 11 correlated poorly between environments (Pearson's r < 0.2), with only one pair (M9-Glucose and 12 synthetic urine media) showing a modest correlation. 13

Despite the poor overall correlations, it is possible that some individual mutations might 14 show stronger relationships than others. Therefore, we disaggregated the data and determined the 15 correlation of fitness effects for each mutation (fig. 7B; supplementary fig. S6). Each data point 16 17 in fig. 7B represents the correlation in fitness effects between two environments for an AMR 18 mutation introduced into multiple genetic backgrounds. In general, the mutation-specific 19 correlations were highly dependent on the environments under comparison, with only gyrB 20 mutations yielding consistently positive correlations. The strongest overall environmental correlation, between M9-Glucose and synthetic urine media, was driven by positive correlations 21 22 for the fluoroquinolone mutations (gyrA, gyrB, and marR mutations). In contrast, the lack of

correlation observed between synthetic urine and synthetic colon media fitness effects was
 driven by a combination of positive and negative mutation-specific correlations, suggesting that
 genetic backgrounds associated with higher costs in synthetic urine medium were associated with
 reduced costs in synthetic colon medium and vice versa.

5 Variation in the strength of correlation between environments is indicative of mutation by genetic background by environment (G x G x E) interactions. Mutations with high correlations in 6 7 fitness effects can be considered to have low levels of genetic background by environment (G x E) interaction, i.e., different genetic backgrounds respond similarly to both environments. On the 8 other hand, a low correlation indicates high levels of G x E interaction, i.e., environmental 9 effects on fitness depend on the genetic background. By this logic, the differences in correlations 10 that we observe between mutations are indicators of G x G x E interactions, since the level of G 11 x E interaction changes depending on the mutation. Although our sampling of genetic 12 backgrounds is too sparse to make strong claims about mutation-level correlations, the variation 13 in correlation coefficients that we observe in fig. 7B further supports that G x G x E interactions 14 underlie the AMR mutation fitness effects. 15

16

Genetic background fitness and phylogenetic relatedness are poor
 predictors of fitness effects

19

Although the experimental data show that genetic background is a significant source of variation on AMR fitness effects, further information about the isolates might help untangle the genetic background effects. We investigated whether two properties of the genetic backgrounds

might explain the variation in fitness effects: their comparative relative fitness in each 1 environment, and their phylogenetic relatedness. Beneficial mutations are expected to have 2 smaller effect sizes for starting genotypes closer to a fitness peak (i.e., well-adapted to the 3 growth medium) than genotypes further from the peak (Wang et al. 2016). However, less is 4 known about the expected magnitude of fitness effects for deleterious mutations at different 5 distances from the peak (Diaz-Colunga et al. 2023). Therefore, we investigated whether any 6 correlation existed between the starting fitness of the genetic backgrounds and the fitness effects 7 8 of the introduced AMR mutations. We estimated genetic background fitness in each of the four growth environments by competing each of the 12 unmutated isolates against a common 9 competitor (supplementary fig. S8A). We observed some variation in the background fitness of 10 the isolates, suggesting that some genotypes were better adapted to each growth environment 11 than others. However, apart from a weak positive correlation in the M9-Glucose environment 12 (fig. 8A; supplementary fig. S9), we found no evidence that background fitness could predict the 13 14 fitness effects of AMR mutations. We also tested whether phylogenetic relatedness could predict differences in fitness 15 effects observed between genetic backgrounds. We reasoned that closely related genetic 16 backgrounds would be more likely to share mutations that interact with the introduced AMR 17 mutations, and would hence exhibit more similar fitness effects. We constructed a whole-genome 18 19 maximum-likelihood phylogeny of our genetic backgrounds, from which we calculated genetic 20 distances between all pairs of strains. We found weak positive correlations between differences 21 in fitness effects and genetic distance for the M9-Glucose and synthetic urine media (fig. 8B),

23 responsible for the positive correlations observed for the M9-Glucose and synthetic urine media

but no correlation for the LB and synthetic colon media. Interestingly, a subset of mutations was

(supplementary fig. S10). Nevertheless, despite these exceptions, our analysis suggests that
 genetic background fitness and phylogenetic relatedness were poor overall predictors of AMR
 mutation fitness effect variation.

4

## 5 **Discussion**

6

The predictability of evolutionary processes depends crucially on the impact of 7 environmental and genetic variation on the fitness effects of mutations. Given the threat of 8 antimicrobial resistance (AMR) to human health, knowledge of the factors determining the 9 fitness effects of AMR mutations has important implications for antimicrobial stewardship. To 10 the extent that resistance mutations are generally costly, antibiotic restriction is expected to 11 reduce the prevalence of resistance. However, if costs of resistance are highly variable because 12 they depend on environment and/or genetic background, then resistance might persist in 13 favorable environmental or genetic refuges. Thus, we sought to measure, and ultimately predict, 14 the effects of genetic background and environment on the fitness of AMR mutants. 15 We systematically measured the fitness effects of 7 resistance mutations across a range of 16 17 E. coli genetic backgrounds and environments. The 12 genetic backgrounds included a standard laboratory strain and 11 clinical isolates, and the four growth environments included standard 18 19 laboratory media, as well as media designed to mimic important sites of infection for E. coli.

AMR mutations caused fairly uniform increases in resistance itself (fig. 2) and were on average costly in the absence of antibiotics (fig. 3). However, the magnitudes of their impacts on fitness

22 were highly variable (fig. 3). Importantly, these fitness effects could not be predicted simply by

knowing the identity of the resistance mutation, but instead depended to varying degrees on the

assay environment, the genetic background of the host strain, and interactions between individual
 terms. These complex interactions rendered the fitness effects of resistance mutations highly
 unpredictable.

Genotype-by-environment interactions are well documented in the quantitative and 4 evolutionary genetics literature. Across a broad range of organisms, mutations may have 5 drastically different effects in different environments (reviewed in Des Marais et al. 2013; Rauw 6 and Gomez-Raya 2015). Likewise, there is growing evidence that AMR mutations, although 7 8 typically deleterious, can have widely varying fitness effects depending on the environmental context (Trindade et al. 2012; Durão et al. 2015; Gifford et al. 2016; Clarke et al. 2020). We 9 similarly find that the fitness effects of resistance mutations depend on the assay environment -a10 given mutation may be deleterious in some environments but neutral on average in others (fig. 3, 11 GyrB (D426N)), or even beneficial in some environments but not others (e.g., the beneficial 12 effect of MarR (R77H) in synthetic colon medium). Although not the focus of the study, several 13 14 genotype-by-environment interactions we observed have biologically plausible mechanisms based on the presence of specific constituents or nutritional complexity of the media. For 15 example, marR mutations, which cause elevated expression of the AcrAB-TolC multidrug efflux 16 pump (Oethinger et al. 1998; Alekshun and Levy 1999; Barbosa and Levy 2000), could be 17 beneficial in synthetic colon medium due to increased efflux of bile salts, a known substrate of 18 19 the pump (Rosenberg et al. 2003). Similarly, differential fitness effects of RpoB (H526Y) 20 mutations are thought to reflect alterations to global transcription that are beneficial specifically during growth in nutritionally poor media (Conrad et al. 2010). 21

In addition to widespread G x E, we found that the fitness effects of AMR mutations
depend on genetic context. In contrast to the relatively uniform effects of the mutations on

1	resistance (fig. 2), the fitness effects in the absence of antibiotics could be deleterious, neutral, or
2	beneficial depending on the genetic background. Our results reinforce the conclusions of
3	empirical studies demonstrating the influence of genetic background on AMR fitness costs
4	(Wong 2017). Trindade et al. (Trindade et al. 2009) observed widespread epistasis among AMR
5	mutations in E. coli, with combinations of resistance mutations introduced in the same genetic
6	background frequently exhibiting non-additive fitness effects. Similarly, but at a larger
7	phylogenetic scale, Vogwill et al. (2016) identified large variation in the costs of rifampicin-
8	resistance mutations across 8 different species within the genus Pseudomonas, with much of the
9	variance attributed to the interaction between mutation and genetic background. Taken together,
10	these experimental studies suggest that the costs of AMR are strongly influenced by epistatic
11	interactions between AMR mutations and other loci over broad scales of relatedness, ranging
12	from single nucleotide to strain and species level differences.
13	Our multi-factorial study design also allowed us to detect three-way interactions between
14	mutation, background genotype, and environment (fig. 7). Here, different resistance mutations
15	demonstrate contrasting G x E interactions. For example, fitness effects across genetic
16	backgrounds are well correlated for MarR (R77H) between synthetic urine and M9-Glucose
17	media (i.e., low G x E), but not for RpoB (H526Y) (i.e., high G x E). Relatedly, we also find that
18	overall levels of epistasis between mutations and genetic backgrounds differ from one
19	environment to another (fig. 4C). Crucially, G x G x E interactions make it difficult to predict
20	costs of resistance between environments, implying that mutation-genotype combinations will
21	respond idiosyncratically to a change in environment. Thus, estimates of fitness using standard
22	lab strains or growth environments may be poor predictors of fitness in clinical settings, limiting
23	our ability to predict which types of resistance will respond to antibiotic restriction, and how

quickly they will do so. Furthermore, although resistance (as measured by MIC) was similar
 across genotypes, resistance was only assessed in LB medium, and it is possible that growth in
 alternative growth environments could reveal G x E interactions undermining this predictability.

The complex gene by environment interactions underpinning the mutational fitness 4 5 effects in our experimental dataset provided a test case for the ability of a fitness landscape model to statistically reproduce the observed patterns in the data. For this purpose, we chose one 6 7 of the simplest probabilistic fitness landscape models, the Rough Mount Fuji (RMF) model, which features tunable epistasis with few parameters and thus lends itself as a base model to test 8 hypotheses regarding the consequences of epistasis in evolution (Bank 2022). Although the RMF 9 model does not incorporate any explicit expectations of how a fitness landscape may differ 10 between environments, its probabilistic nature results in a large variation of fitness landscapes 11 that can be produced under the same parameters. Therefore, we tested 1) how well the model 12 could fit the data of each single environment, and 2) whether it could accommodate the data 13 from all environments with the same set of parameters. We found that the RMF model was able 14 to fit the statistics of individual environments well (fig. 6), considering the variation in fitness 15 16 effects observed across genetic backgrounds. The model parameters suggest substantial epistasis for all environments, with the standard deviation of the epistatic contribution to the fitness 17 effects typically larger than the standard deviation of the mean additive contribution. Although 18 19 the RMF model could accommodate the fitness effect statistics for each environment separately, we found that no set of parameters could successfully explain the same statistics when all 20 21 environments were considered together. In other words, the fitness landscapes in different 22 environments could not be described as independent draws from a model with common 23 parameters. We conclude that because even the most general features of the underlying fitness

landscape (i.e., the average additive and epistatic contributions to fitness) are irreconcilable
 between environments, successful prediction of fitness will require sophisticated models that
 incorporate additional, environment-specific factors.

The failure of our RMF-like model to predict fitness across environments raised the question 4 5 of what additional information would be required. We investigated two possibilities here phylogenetic relatedness, and relative fitness of the ancestral genotypes. Phylogenetic relatedness 6 7 could in principle help to predict epistatic interactions, since closely related genotypes share more polymorphisms than distant relatives. The fitness effects of focal resistance mutations 8 should be similar for close relatives to the extent that these effects are modulated by these shared 9 polymorphisms. However, we found no correlation between relatedness and the fitness effects of 10 resistance mutations (fig. 8B). One potential explanation for this lack of correlation is that 11 different mutations which interact with our focal resistance mutations arise so frequently that 12 they are not shared even between closely related genotypes. It is also possible that complex 13 genetic interactions between mutations modulate fitness effects such that phylogenetic 14 relatedness may not provide enough resolution to be predictive. 15

Alternatively, the fitness effects of a mutation may not be determined by specific interactions 16 with other mutations in a given genetic background, but rather by global properties of a 17 18 genotype. Fitness is a clear candidate for such a property – in the widely observed phenomenon of 'diminishing returns' epistasis, beneficial mutations confer a smaller gain for genotypes with 19 20 higher starting fitness (Khan et al. 2011; Kryazhimskiy et al. 2014; Perfeito et al. 2014; Wang et 21 al. 2016). Wang et al. (2016), for example, provided clear evidence that the fitness effects of 22 several beneficial mutations were predicted well by the fitness of the ancestral genotype, but not 23 by relatedness or by metabolic similarity. Likewise, there is some theoretical and empirical support for 'increasing costs' epistasis, in which deleterious mutations are more costly on fitter
genetic backgrounds (Diaz-Colunga et al. 2023; Johnson et al. 2023). In our dataset, we found
some evidence for 'diminishing returns' epistasis for level of resistance (supplementary fig. S1)
- that is, for the trait towards which these mutations provide a direct benefit. However, there was
no evidence that 'increasing costs' epistasis underlies the fitness effects in the absence of drug
(fig. 8A).

7 We suggest that predictability may be improved by specific information concerning the assay environments. Characteristics of environments that could be quantitatively compared, such as 8 nutrient concentrations, could be valuable to inform the direction in which the model should be 9 expanded to account for differences between environments. It is worth noting that, overall, 10 fitness effects were best correlated between the M9-Glucose and synthetic urine media (fig. 7A). 11 These environments offer lower nutritional complexity than do LB and synthetic colon media, 12 both of which contain relatively large amounts of complex nutrient mixtures (e.g., tryptone). 13 Further exploration of the impact of nutritional environment on predictability may thus be 14 warranted. 15

In conclusion, this study provides a systematic view of the impact of both genetic 16 background (i.e., epistasis) and environment (i.e., G x E interactions) on the fitness effects of 17 18 AMR mutations. In the context of antimicrobial stewardship, our results suggest that the 19 response of resistant bacteria to antibiotic restriction might be difficult to predict. The outcome 20 of a restriction protocol might depend on the genetic background(s) of the resistant microbial population and on the availability of environment refuges where costs are diminished. 21 22 Nevertheless, although we found that in some genetic and environmental contexts AMR 23 mutations were neutral or beneficial, overall the mutations tended to be costly and variation in

fitness effects was driven more by differences in the magnitudes of the costs rather than changes 1 in sign from costly to beneficial (supplementary fig. S4). Thus, to the extent that our findings 2 translate to clinical settings, we would expect antibiotic restriction interventions to be successful 3 on average in reducing the prevalence of resistance, but at an unpredictable pace. Furthermore, 4 some mutations were more consistently costly across environments and genetic backgrounds 5 (i.e., RpsL (K43R) and RpoB (S531L)), suggesting that knowledge of the mutation could 6 provide some level of predictive value for antibiotic restriction outcomes. In addition, our study 7 8 calls for the further development of fitness landscape models across environments and their evaluation in the light of data such as those presented in this study. Such models could help 9 identify the variables that influence predictability and inform subsequent experimental study 10 11 design.

12

# **Materials and Methods**

14

#### 15 Bacterial strains, growth conditions, and antibiotics

16

The *E. coli* isolates sampled for AMR mutagenesis include the K-12 reference strain
(MG1655) (Blattner et al. 1997), six extra-intestinal isolates collected from patients during the
2007-11 CANWARD survey of antibiotic-resistant pathogens in Canada (Zhanel et al. 2013;
Basra et al. 2018), and three enterohemorrhagic strains from the Ottawa Laboratory Carling

I	culture conection (McCaltiny 2020). Additional E. Cou strains used for molecular cioning
2	procedures include DH5 $\alpha$ $\lambda$ pir and WM3064 (Saltikov and Newman 2003).
3	Bacteria were routinely cultured at 37 °C in LB broth (Sambrook and Russell 2001) with
4	shaking (150 rpm) and plated on LB with 1.5% agar. Antibiotics were added to LB media from
5	stocks prepared at the following concentrations: Ampicillin (100 mg/ml in water), Ciprofloxacin
6	(10 mg/ml in 0.1 M NaOH), Rifampicin (50 mg/ml in DMSO), Streptomycin (100 mg/ml in
7	water). Media were also supplemented when appropriate with 0.2% Arabinose (from sterile-
8	filtered 10% solution in water), 5-10% Sucrose (from sterile-filtered 50% solution in water), 0.3
9	mM Diaminopimelic acid (DAP; from 60 mM solution in water), 1 mM IPTG (from 100 mM
10	solution in water), 40 µg/ml X-Gal (from 20 mg/ml solution in Dimethylformamide).
11	

(MaConthy 2020) Additional E cali strains used for malacular elemina

#### 12 Construction of AMR mutants by site-directed mutagenesis

13

AMR mutations were introduced into E. coli genomes by oligonucleotide-mediated 14 recombineering as described by Lennen et al. (Lennen et al. 2016). The Lambda Red plasmid 15 (pMA7-SacB) encodes arabinose inducible Lambda Beta and Dam methylase functions. Lambda 16 17 Beta promotes chromosomal recombination of single-stranded DNA with short (< 100 base pair) regions of homology (Ellis et al. 2001), while Dam methylase induction increases recombination 18 efficiency by transiently disabling the E. coli DNA mismatch repair system (Lennen et al. 2016). 19 Recombineering oligonucleotides were designed with the MAGE Oligonucleotide Design Tool 20 (MODEST) (Bonde et al. 2014), and encoded AMR point mutations centered within 90 bp of 21 22 sequence homologous to E. coli (MG1655) genomic sites (supplementary table S1).

Oligonucleotides were synthesized by Integrated DNA Technologies (standard desalting with no
 additional purification) and suspended in water to 100 μM. pMA7-SacB was a gift from Morten
 Sommer (Addgene plasmid # 79968; http://n2t.net/addgene:79968; RRID: Addgene\_79968).
 pMA7-SacB was transformed into *E. coli* strains by electroporation with selection on LB agar
 with 100 μg/ml ampicillin (or 6400 μg/ml ampicillin for the β-lactam resistant isolate PB6).

6 Site-directed mutagenesis was performed according to the protocol described by Lennen 7 et al. (Lennen et al. 2016). Strains carrying pMA7-SacB were inoculated in LB broth with ampicillin, incubated overnight at 37 °C with shaking, subcultured (1:100) in LB with ampicillin, 8 and incubated for another 2-3 h. Arabinose (0.2%) was added to the cultures to induce Lambda 9 Beta and Dam methylase functions. Cultures were incubated for 15 min at 37 °C with shaking, 10 then transferred to an ice bath and chilled for 15 min. Electrocompetent cells were prepared by 11 pelleting 10 ml of culture, resuspending and pelleting the cells three times with ice-cold sterile 12 water (twice with 5 ml and once with 1 ml), with a final resuspension in 0.25 ml ice-cold water. 13 For each electroporation, 25 µl of competent cells were mixed with 25 µl of oligonucleotide 14 (diluted to 4 µM in water) in an Eppendorf tube, transferred to a chilled 0.2 cm cuvette (Bio-15 16 Rad), and electroporated at 2.5 kV (Bio-Rad MicroPulser; Ec2 setting). Cells were suspended in 3 ml LB broth and incubated with shaking overnight in test tubes. 17

Mutants were selected by plating serial dilutions of the cultures on LB agar supplemented with the antibiotic corresponding to the introduced mutation (ciprofloxacin:  $0.025-0.05 \mu g/ml$ ; rifampicin: 25-50 µg/ml; streptomycin: 25-50 µg/ml). Successful transformations yielded higher colony counts (typically 10<sup>4</sup> to 10<sup>6</sup> cfu/ml) on the selective media in comparison to negative controls (i.e., cells electroporated with no added oligonucleotide). Candidate mutants were streaked on LB containing 5% sucrose to cure strains of the Red plasmid by SacB-mediated

1	counterselection (Blomfield et al. 1991; Lennen et al. 2016). Successfully introduced mutations
2	were identified by sequencing (Genome Quebec) PCR products amplifying the genomic locus
3	targeted by the recombineering oligonucleotide (supplementary table S2).
4	The final mutant library comprised 67 sequence-confirmed mutants, with 17 mutants
5	unable to be constructed for the following reasons. Thirteen mutants were not constructed in

cases where the ancestor exhibited elevated resistance to the respective antibiotic. PB10, PB13,
and PB15 already harbored the *gyrA* mutations (S83L and D87N) and their fluoroquinolone
resistance compromised selection of *gyrB* and *marR* mutants. Likewise, although PB6 and
OLC969 did not originally harbor mutations in *rpsL*, their high intrinsic streptomycin resistance,
presumably by other mechanisms, compromised selection of *rpsL* mutations. Finally, the
recovery of four mutants failed despite their attempted construction (*gyrB* mutations in PB6 and
OLC969; *rpoB* S531L in PB1 and PB4).

13

# 14 Construction of YFP-marked E. coli strains

15

We marked *E. coli* strains with yellow fluorescent protein (YFP) to distinguish bacteria
by fluorescence in competitive fitness assays. A constitutive YFP expression cassette was
inserted in the chromosome of *E. coli* isolates, replacing *lac* operon sequences (Ullmann 2009)
spanning 62 bp upstream from the *lacI* start codon to 56 bp upstream from the *lacA* stop codon.
We constructed a custom allelic replacement (AR) plasmid (pR6KT-SacB-*ΔlacIZYA*::YFP) with
YFP sequences flanked by *lac* operon-targeting sequences on a suicide plasmid (pR6KT-SacB)
(Lebeuf-Taylor et al. 2019; Hinz et al. 2022) that replicates only in hosts carrying the lambda pir

1	gene (Rakowski and Filutowicz 2013). Selectable (ampicillin and tetracycline resistance genes)
2	and counterselectable (sacB) markers on the plasmid facilitate two-step allelic exchange between
3	plasmid and chromosomal sequences (Melnyk et al. 2017; Lebeuf-Taylor et al. 2019). We used
4	the primers listed in supplementary table S2 to PCR-amplify the YFP cassette from a source
5	plasmid (pAH1T-P <sub>A1/04/03</sub> -YFP) (Hinz et al. 2022) and the <i>lac</i> targeting sequences from MG1655
6	chromosomal DNA. The three PCR products were spin-column purified and ligated to pR6KT-
7	SacB in one-pot Golden Gate assembly reactions containing the Type IIS restriction enzyme
8	BsaI and T4 DNA ligase, as described by Hinz et al. (Hinz et al. 2022). Assembly reactions were
9	transformed into chemically competent E. coli DH5 $\alpha$ $\lambda$ pir by the Inoue method (Sambrook and
10	Russell 2001), and ampicillin-resistant clones carrying the assembled YFP AR plasmid were
11	identified based on PCR screening and detection of fluorescence in liquid cultures.
12	The allelic replacement procedure involved plasmid conjugation from donor to recipient
13	E. coli strains, followed by two sequential recA-mediated recombination events between
14	homologous sequences shared by the plasmid and recipient chromosome. The YFP AR plasmid
15	was transformed into the auxotrophic donor strain WM3064, a pir-expressing E. coli that
16	requires diaminopimelic acid (DAP) supplementation in growth media (Saltikov and Newman
17	2003). Conjugations were performed between the plasmid-bearing donor (grown in LB with 0.3
18	mM DAP and 100 $\mu$ g/ml ampicillin) and recipient strains on LB agar containing 0.3 mM DAP.
19	Exconjugates harboring chromosomally integrated plasmid were selected on LB agar containing
20	100 $\mu$ g/ml ampicillin or 10 $\mu$ g/ml tetracycline (selecting for recombinant recipients) and lacking
21	DAP (preventing growth of the WM3064 donor). Selection for the second recombination event
22	(loss of AR plasmid sequences) was accomplished by plating the exconjugates on LB agar
23	containing 10% sucrose, to eliminate genotypes carrying the plasmid-borne sacB gene. Sucrose

resistance could result from chromosomal excision of plasmid backbone sequences, leading to
either replacement of the *lac* operon with the YFP cassette or reversion to the wild-type *lac*+
sequence. These two possibilities were distinguished by including 1 mM IPTG and 40 µg/ml XGal in the sucrose selection media, enabling blue-white screening of *lac* genotypes. White (*lac-*)
sucrose-resistant colonies were subsequently screened for loss of plasmid antibiotic resistance
markers and presence of fluorescent signal.

The YFP cassette was successfully transferred into 7 *E. coli* genetic backgrounds:
MG1655, PB1, PB4, PB13, PB15, OLC682, and OLC969. Introduction of the marker failed in
the remaining 5 genetic backgrounds (PB2, PB5, PB6, PB10, OLC809) due to the inability to
select for successful recombinants during the allelic replacement procedure.

11

#### 12 Minimum inhibitory concentration assays

13

Antibiotic susceptibilities of AMR mutants and their ancestors were determined by broth 14 dilution Minimum Inhibitory Concentration (MIC) assays (Andrews 2001). Two-fold serial 15 dilutions of antibiotics were prepared in 100 µl of LB broth in 96-well plates, and 100 µl of 1: 16 1:1000 diluted *E. coli* overnight cultures (approx.  $3 \times 10^5$  cells) were added to each well. Similar 17 overnight culture densities were observed among ancestral genotypes (see supplementary fig. 18 19 S2); therefore, inoculum differences were unlikely to confound the MIC comparisons. Plates 20 were incubated statically at 37 °C for 20 h, and the  $OD_{600}$  of each well was measured with a 21 microplate reader (Biotek Synergy H1). MICs were defined as the lowest antibiotic 22 concentration yielding an OD<sub>600</sub> signal of 0.15 after subtraction of values for uninoculated

blanks. The following antibiotics and two-fold concentration ranges were tested: ciprofloxacin 1  $(0.003125 \text{ to } 204.8 \,\mu\text{g/ml})$ , rifampicin (3.125 to 3200  $\mu\text{g/ml})$ , and streptomycin (3.125 to 3200 2 µg/ml). MICs for each of the antibiotics were determined for all 67 AMR mutants and their 12 3 ancestors in three replicate assays inoculated from the same overnight cultures. Two *rpoB* 4 mutants [PB4 RpoB (H526Y) and PB15 RpoB (S531L)] and all except one rpsL mutant [PB13 5 RpsL (K43R)] grew at the maximum tested concentrations (3200 µg/ml) of rifampicin and 6 streptomycin, respectively. Their MICs (6400 µg/ml) should be considered lower-bound 7 8 estimates, and therefore, variation in streptomycin resistance among *rpsL* mutants was not accurately determined. Plots show the median fold change in MIC due to mutation for the three 9 replicate estimates (calculated by dividing the MIC of the mutant by the median MIC of the 10 11 ancestor).

Differences in antibiotic susceptibility caused by the introduced mutations across 12 different genetic backgrounds were determined by a multiple comparison t-test in R Version 13 14 4.2.2 (R Core Team 2021) with the compare\_means function in the ggpubr package. Median fold-changes in MIC (log<sub>2</sub>-transformed) were compared between mutants and ancestors (with 15 antibiotic as a grouping variable) and significance was assessed using Bonferroni-adjusted p-16 values. The predictability of MIC fold increases was determined by fitting a mixed-effect linear 17 model using the lmer function in the lme4 package. The model predicts the fold-change in MIC 18 19 (log<sub>2</sub>-transformed) for target antibiotics from the identity of the introduced mutation (fixed 20 effect), with the genetic background and interaction between genetic background and mutation included as random effects. Correlations between MIC fold-increases and ancestral MIC were 21 22 determined using stat cor in the ggpubr package.

# 1 Growth media and carrying capacity estimates

3	Competition experiments were performed in lysogeny broth (LB), M9-Glucose, synthetic
4	urine medium, and synthetic colon medium. LB and M9-Glucose were prepared as described
5	(Sambrook and Russell 2001). Synthetic urine medium is a defined medium containing 416 mM
6	urea and 10 mM creatinine and was modified from published recipes (Laube et al. 2001; Clarke
7	2018) by the addition of 0.001% Casamino acids to augment bacterial growth. Synthetic colon
8	medium is a tryptone-based medium supplemented with 0.4% bile salts and was prepared as
9	described (Polzin et al. 2013). The concentrations of each media component and details on
10	preparation are found in supplementary tables S3, S4, S5, and S6.
11	The carrying capacity was assessed for each ancestral isolate following 20 h of growth in
12	each competition growth medium. Isolates were inoculated in duplicate in LB broth and
13	incubated 24 h at 37 °C with shaking. Cultures were diluted (1:100) into each of the competition
14	growth media (LB, M9-Glucose, synthetic urine medium, and synthetic colon medium) and
15	incubated 24 h for media acclimation. Acclimated cultures were diluted (1:100) into fresh
16	competition growth media and incubated for 24 h. Growth yields were determined by plating
17	serial dilutions of the cultures on LB agar, and calculating the number of colony forming units
18	per ml.
19	
20	
21	
22	

#### **1** Competitive fitness assays

2

Relative fitness was determined in head-to-head competitions (Melnyk et al. 2015). 3 4 between unmarked AMR mutant constructs and YFP-marked competitors co-cultured in each growth environment (LB, M9-Glucose, synthetic urine medium, and synthetic colon medium). 5 Focal strains were competed against isogenic YFP-marked competitors or, when the isogenic 6 7 competitor could not be constructed, a common competitor (MG1655-YFP). Four replicate competitions derived from independently inoculated cultures were performed for each genotype 8 by environment combination. Pure cultures of unmarked mutants, unmarked ancestral isolates, 9 and YFP-marked competitors were prepared in 24-well microplates by inoculating 1.5 ml of 10 competition growth medium with colonies from freshly streaked LB plates. After 24 h of 11 incubation at 37 °C with 150 rpm shaking, 100 µl of each unmarked strain was mixed with 100 12 µl of its corresponding YFP-marked competitor. 15 µl of each mix was diluted in 1.5 ml growth 13 medium (1:100 dilution), and the remainder was reserved for immediate flow cytometry analysis 14 (initial timepoint). After 24 h of incubation at 37 °C, competition cultures were analyzed by flow 15 cytometry (final timepoint). 24 h was determined to be sufficient incubation time for cultures to 16 17 reach stationary phase. Therefore, the number of generations of growth during the competitions was estimated as 6.64, the number of doublings required to reach stationary phase following the 18 19 1:100 dilution (i.e.,  $\log_2(100) \approx 6.64$ ). The relative frequencies of unmarked and YFP-marked cells in initial and final timepoints of the competitions were determined by flow cytometry 20 21 analysis. Cultures were diluted in 1 ml of freshly filtered (0.2 µm pore size) 1X M9 salts prior to 22 analysis (1:1000 for LB, 1:500 for M9-Glucose, 1:50 for synthetic urine medium, and 1:500 for synthetic colon medium). Cells were counted using a Gallios Flow Cytometer (Beckman 23

Coulter) with a minimum of 20,000 counts per sample. Fluorescence was detected using the 488 1 nm excitation laser and 525/40 nm detection filter. Numbers of fluorescent and non-fluorescent 2 cells were estimated using Kaluza analysis software. Signal thresholds for distinguishing 3 fluorescent from non-fluorescent cells were established for each YFP-marked genotype by 4 analyzing pure cultures of marked and unmarked strains. To distinguish cells from non-specific 5 particles, gates were drawn in forward vs. side scatter plots that maximized the proportion of 6 YFP-positive counts in pure cultures. The number of unmarked cells in each sample were 7 8 estimated by subtracting the number of YFP-positive gated counts from the total number of gated 9 counts.

10

#### **11 Relative fitness calculations**

12

Relative fitness (ω) was calculated as previously described (Melnyk et al. 2015) from the
initial (*i*) and final (*f*) counts of the unmarked focal (*n*1) and marked competitor (*n*2) strains and
the number of generations (estimated as 6.64 as described above):

16

17 
$$\omega = 1 + \frac{ln\left(\frac{n_{1f}}{n_{1i}}\right) - ln\left(\frac{n_{2f}}{n_{2i}}\right)}{No. of generations}$$
(Eq. 1)

To account for fitness effects caused by the YFP marker or use of a non-isogenic competitor, the relative fitness value for each AMR mutant was divided by the relative fitness of its wild-type ancestor (competed against the same YFP-marked strain). These scaled fitness values, therefore, indicate the effects of the introduced AMR mutations alone. The common competitor MG1655-YFP was used for competitions involving genetic backgrounds OLC809, PB2, PB5, PB6, and

PB10. In control experiments, we determined that MG1655-YFP was a valid common 1

competitor since strong negative interactions were not observed between MG1655-YFP and the 2

5 ancestral strains (supplementary fig. S11). Furthermore, similar relative fitness trends were 3

observed in competitions regardless of whether an isogenic or common competitor was used 4

5 (supplementary fig. S12).

Variance component analysis of the relative fitness estimates was performed in R using 6 the lmer function in the lme4 package. For each mutation, a random effects model was fit that 7 8 included genetic background, environment, and their interaction as random factors contributing to variance in relative fitness. The plots show the fitness effects variance explained by each 9 random effect, as well as the proportion of total variance explained. 10

11

#### **Epistasis analysis** 12

13

To quantify epistasis, we used the gamma statistic ( $\gamma$ ), introduced by (Ferretti et al. 2016). 14  $\gamma$  is defined as the average correlation of fitness effects across diverse genetic backgrounds in 15 which a mutation manifests. This can be mathematically expressed as 16

$$\gamma = \frac{\sum_{g} \sum_{g' \neq g} \sum_{i} s_i(g) \cdot s_i(g')}{(L-1) \sum_{g} \sum_{i} s_i^2(g)},$$
(Eq. 2)

1

where g and g' index all possible genotypes, i all existing mutations, and  $s_i(g)$  represents the 18 19 effect of mutation *i* in the *g* background.

20 When the correlation is close to 1, the effect of the mutations is relatively consistent 21 across the genetic backgrounds they appear, implying minimal epistasis. As the value of  $\gamma$ 

decreases, the correlation between mutation effects in different backgrounds weakens, indicating
more pronounced epistasis. In the extreme, when the correlation approaches zero, the mutation
effects in different genetic backgrounds become independent, signifying the highest level of
epistasis.

5 In supplementary fig. S4, we present an additional measure of epistasis, the difference in 6 fitness effects when the genetic background is changed. We present its absolute value as this 7 difference can be positive or negative. We further partition this epistasis into two categories: 8 magnitude epistasis, where the direction of the fitness effect remains consistent, and sign 9 epistasis, where a mutation transitions from advantageous to deleterious (or vice versa) when its 10 genetic background is modified.

11

#### 12 Modeling

13

We employed a general version of the Rough Mount Fuji (RMF) model to try to capture the essential statistical features of the data. The model considers a genotype composed of *L* diallelic loci. Each allele is assigned an additive effect; on top of the additive effect, an epistatic component specific to each genotype is added. We treat both contributions as normally distributed random variables. This way, the fitness of a genotype *g* is given by

19 
$$f(g) = \sum_{i=1}^{L} a_i g_i + b(g),$$
 (Eq. 3)

where a<sub>i</sub> ~ N(μ<sub>a</sub>, σ<sub>a</sub>) and b(g) ~ N(0, σ<sub>b</sub>); i.e., the additive contributions a<sub>i</sub> of each locus i
follow a normal distribution with mean μ<sub>a</sub> and standard deviation σ<sub>a</sub> and the epistatic
components b(g) follow a normal distribution with zero mean and standard deviation σ<sub>b</sub>. Each
allele g<sub>i</sub> takes the values one or zero, indicating the state of locus i in genotype g, with a value
of one denoting a resistance mutation present in the genotype and the value of zero marking the
absence of a resistance mutation at that locus.

7 This model produces a fitness effect  $s_j(i)$  of a mutation *i* in a background *j* given by

8 
$$s_j(i) = f(g_{[i]}) - f(g) = a_i + b(g_{[i]}) - b(g)$$
 (Eq. 4)

9 where g is the genotype of the background j and  $g_{[i]}$  the genotype of the background with the 10 mutation in locus *i*.

To compare the model's predictions to the data, we constructed a fine grid of pairs of  $\sigma_a$ and  $\sigma_b$ , for  $\sigma_{a/b} \in [0,0.24]$  with intervals of 0.002. We assumed the mean fitness effect in the model, represented by the parameter  $\mu_a$ , to be equal to the mean of the experimentally measured fitness effects. For each of these pairs, we generated 10<sup>6</sup> instances of the model and calculated three summary statistics of the landscape: the mean of fitness effects, the variance of fitness effects, and the gamma epistasis parameters. We used this generated data to obtain the distribution of each summary statistic.

With these distributions, we estimated the likelihood of obtaining the data statistics given
the set of model parameters for each summary statistic. In the plots, the likelihood values are
represented relative to the maximum likelihood, so all log-likelihoods shown have a maximum of
0.

To compute the experimental data statistics, we used a parametric bootstrap assuming
that the fitness effects' replicate values are normally distributed, taking the mean and standard
variation of the replicates as the normal distribution parameters. We also used an alternative
bootstrap strategy that produced no qualitative changes in the results, as a test to the assumption's
robustness.

6

# 7 Analytical estimates of the parameters

8

9 A simpler approach is matching the statistics' mean values directly to the model's 10 parameters. This method is possible to calculate analytically but less statistically robust since it 11 does not consider the variation among replicates. Eq. 4, shows that the mean  $\mu$  of the fitness 12 distribution and the corresponding variance  $\sigma_s^2$  are given respectively by

13  $\mu = \mu_a$ ,

14 and

15  $\sigma_s^2 = \sigma_a^2 + 2\sigma_b^2$ .

16 The mean  $\gamma$  parameter is approximated for RMF model as (Ferretti et al. 2016)

$$E[\gamma] \approx 1 - \frac{2\sigma_b^2}{\mu_a^2 + \sigma_a^2 + 2\sigma_b^2}$$
. (Eq. 5)

18 Equating these values to their experimental means  $\overline{\mu}$ ,  $\overline{\sigma_s^2}$  and  $\overline{\gamma}$  we can solve the system and find

$$\begin{cases} \mu_a = \mu, \\ \sigma_a = \sqrt{\overline{\sigma_s^2} - (1 - \overline{\gamma})(\overline{\mu}^2 + \overline{\sigma_s^2})}, \\ \sigma_b = \sqrt{(1 - \overline{\gamma})(\overline{\mu}^2 + \overline{\sigma_s^2})/2}, \end{cases}$$
(Eq. 6)

which corresponds to an estimate of the best model parameters based only on the experimental
mean values of the statistics. These provide good estimates for the best parameters for the case of
single environment landscapes, but fail to describe multiple environment landscapes because the
distribution of the statistics is not well approximated by their mean value.

6

#### 7 Analysis of genetic relatedness

A whole-genome phylogeny was generated using the REALPHY webserver (Bertels et al. 2014)
(https://realphy.unibas.ch/realphy/). FASTA formatted genome sequences were uploaded and
aligned to the reference K-12 (MG1655) sequence using Bowtie2 (Langmead and Salzberg
2012) with default parameters. A maximum likelihood tree was then inferred using PhyML
(Guindon et al. 2010), again with default parameters.

13

# 14 Acknowledgements

- This study was funded by a JPI-AMR grant to AW, RK, and CB (Canadian Institutes of Health
  Research grant no. 150766, FCT grant JPIAMR/0001/2016). AA was supported by ERC Starting
  Grant 804569 (FIT2GO) to CB. CB acknowledges support by SNF project grant
- 19 315230\_204838/1 (MiCo4Sys).

# 1 Data Availability

- 2
- 3 All relevant data are within the manuscript and its Supporting Information files. The code and
- 4 data files underlying the figures and analyses are available in a GitHub repository
- 5 (https://github.com/andreamado/unpredictability\_hinz\_et\_al) and archived in Zenodo (DOI to be

6 provided at proof stage).

7

# 8 **References**

9

Aita T, Uchiyama H, Inaoka T, Nakajima M, Kokubo T, Husimi Y. 2000. Analysis of a local fitness
 landscape with a model of the rough Mt. Fuji-type landscape: application to prolyl endopeptidase
 and thermolysin. *Biopolymers*. 54:64–79.

- Alekshun MN, Levy SB. 1999. The *mar* regulon: multiple resistance to antibiotics and other toxic
   chemicals. *Trends Microbiol*. 7:410–413.
- Andrews JM. 2001. Determination of minimum inhibitory concentrations. *J Antimicrob Chemother*.
  48:5–16.
- 17 Bank C. 2022. Epistasis and Adaptation on Fitness Landscapes. *Annu Rev Ecol Evol Syst.* 53:457–479.
- Bank C, Matuszewski S, Hietpas RT, Jensen JD. 2016. On the (un)predictability of a large intragenic
  fitness landscape. *Proc Natl Acad Sci U S A*. 113:14085–14090.
- 20 Barbosa TM, Levy SB. 2000. Differential expression of over 60 chromosomal genes in Escherichia coli
- by constitutive expression of MarA. *J Bacteriol*. 182:3467–3474.

1	Basra P, Alsaadi A, Bernal-Astrain G, O'Sullivan ML, Hazlett B, Clarke LM, Schoenrock A, Pitre S,
2	Wong A. 2018. Fitness Tradeoffs of Antibiotic Resistance in Extraintestinal Pathogenic
3	Escherichia coli. Genome Biol Evol. 10:667–679.
4	Bertels F, Silander OK, Pachkov M, Rainey PB, van Nimwegen E. 2014. Automated reconstruction of
5	whole-genome phylogenies from short-sequence reads. Mol Biol Evol. 31:1077-1088.
6	Bhardwaj P, Hans A, Ruikar K, Guan Z, Palmer KL. 2017. Reduced Chlorhexidine and Daptomycin
7	Susceptibility in Vancomycin-Resistant Enterococcus faecium after Serial Chlorhexidine
8	Exposure. Antimicrob Agents Chemother. 62:e01235-17.
9	Bhatnagar K, Wong A. 2019. The mutational landscape of quinolone resistance in Escherichia coli. PLOS
10	One. 14:e0224650.
11	Blanquart F, Achaz G, Bataillon T, Tenaillon O. 2014. Properties of selected mutations and genotypic
12	landscapes under Fisher's geometric model. Evolution. 68:3537–3554.
13	Blanquart F, Bataillon T. 2016. Epistasis and the Structure of Fitness Landscapes: Are Experimental
14	Fitness Landscapes Compatible with Fisher's Geometric Model? Genetics. 203:847-862.
15	Blattner FR Plunkett G Bloch CA Perna NT Burland V Riley M Collado-Vides I Glasner ID Rode
16	CK Mayhew GF et al 1997 The Complete Genome Sequence of <i>Escherichia coli</i> K-12
17	Science, 277:1453–1462.
.,	
18	Blomfield IC, Vaughn V, Rest RF, Eisenstein BI. 1991. Allelic exchange in Escherichia coli using the
19	Bacillus subtilis sacB gene and a temperature-sensitive pSC101 replicon. Mol Microbiol. 5:1447–
20	1457.

1	Bonde MT, Klausen MS, Anderson MV, Wallin AIN, Wang HH, Sommer MOA. 2014. MODEST: a
2	web-based design tool for oligonucleotide-mediated genome engineering and recombineering.
3	Nucleic Acids Res. 42:W408-415.
4	Brown EEF, Cooper A, Carrillo C, Blais B. 2019. Selection of Multidrug-Resistant Bacteria in Medicated
0	Annual reeds. Tront Microbiol. 10.450.
6	CDC. 2020. Antibiotic-resistant Germs: New Threats. Centers for Disease Control and Prevention
7	[Internet]. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html
8	Clarke L. 2018. The Effect of Environmental Heterogeniety on the Fitness of Antibiotic Resistant
9	Escherichia Coli. Available from: https://curve.carleton.ca/3ac2116e-80fa-45ba-ab7e-
10	c2ad40101bca
11	Clarke L, Pelin A, Phan M, Wong A. 2020. The effect of environmental heterogeneity on the fitness of
12	antibiotic resistance mutations in <i>Escherichia coli</i> . Evol Ecol. 34:379–390.
13	Conrad TM, Frazier M, Joyce AR, Cho B-K, Knight EM, Lewis NE, Landick R, Palsson BØ. 2010. RNA
14	polymerase mutants found through adaptive evolution reprogram Escherichia coli for optimal
15	growth in minimal media. Proc Natl Acad Sci USA. 107:20500–20505.
16	Council of Canadian Academies. 2019. When Antibiotics Fail: The Expert Panel on the Potential Socio-
17	Economic Impacts of Antimicrobial Resistance in Canada. Available from:
18	http://www.deslibris.ca/ID/10102747
10	Das SG. Direito SO. Waclaw B. Allen RI. Krug I. 2020. Predictable properties of fitness landscapes
20	induced by adaptational tradeoffs <i>eLife</i> 9:e55155
20	maaaaa oy uuupuutonut uuuoonis. chije. 7.000100.

1	Des Marais DL, Hernandez KM, Juenger TE. 2013. Genotype-by-Environment Interaction and Plasticity:
2	Exploring Genomic Responses of Plants to the Abiotic Environment. Annu Rev Ecol Evol Syst.
3	44:5–29.
4	Diaz-Colunga J, Skwara A, Gowda K, Diaz-Uriarte R, Tikhonov M, Bajic D, Sanchez A. 2023. Global
5	epistasis on fitness landscapes. <i>Philos Trans R Soc B</i> . 378:20220053.
6	Dierikx CM, Hengeveld PD, Veldman KT, de Haan A, van der Voorde S, Dop PY, Bosch T, van
7	Duijkeren E. 2016. Ten years later: still a high prevalence of MRSA in slaughter pigs despite a
8	significant reduction in antimicrobial usage in pigs the Netherlands. J Antimicrob Chemother.
9	71:2414–2418.
10	Durão P, Balbontín R, Gordo I. 2018. Evolutionary Mechanisms Shaping the Maintenance of Antibiotic
11	Resistance. Trends Microbiol. 26:677–691.
12	Durão P, Trindade S, Sousa A, Gordo I. 2015. Multiple Resistance at No Cost: Rifampicin and
13	Streptomycin a Dangerous Liaison in the Spread of Antibiotic Resistance. Mol Biol Evol.
14	32:2675–2680.
15	Ellis HM, Yu D, DiTizio T, Court DL. 2001. High efficiency mutagenesis, repair, and engineering of
16	chromosomal DNA using single-stranded oligonucleotides. Proc Natl Acad Sci USA. 98:6742-
17	6746.
18	Enne VI. 2010. Reducing antimicrobial resistance in the community by restricting prescribing: can it be
19	done? J Antimicrob Chemother. 65:179–182.
20	Enne VI, Livermore DM, Stephens P, Hall LM. 2001. Persistence of sulphonamide resistance in
21	Escherichia coli in the UK despite national prescribing restriction. Lancet. 357:1325–1328.

1	Ferretti L, Schmiegelt B, Weinreich D, Yamauchi A, Kobayashi Y, Tajima F, Achaz G. 2016. Measuring
2	epistasis in fitness landscapes: The correlation of fitness effects of mutations. J Theor Biol.
3	396:132–143.
4	Flynn KM, Cooper TF, Moore FB-G, Cooper VS. 2013. The Environment Affects Epistatic Interactions
5	to Alter the Topology of an Empirical Fitness Landscape. <i>PLOS Genet.</i> 9:e1003426.
6	Ghenu A-H, Amado A, Gordo I, Bank C. 2023. Epistasis decreases with increasing antibiotic pressure but
7	not temperature. Philos Trans R Soc B. 378:20220058.
8	Gifford DR, Moss E, MacLean RC. 2016. Environmental variation alters the fitness effects of rifampicin
9	resistance mutations in Pseudomonas aeruginosa. Evolution. 70:725–730.
10	Goldstein BP. 2014. Resistance to rifampicin: a review. J Antibiot. 67:625-630.
11	Guinden & Dufavard I E Lafort V. Anisimova M. Hardiik W. Gasaval O. 2010. Nav. Algorithms and
11	Gundon's, Durayard J-r, Lefort V, Amsinova M, Hordijk W, Gascuer O. 2010. New Algoriumis and
12	Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML
13	3.0. Syst Biol. 59:307–321.
14	Hall AR. 2013. Genotype-by-environment interactions due to antibiotic resistance and adaptation in
15	Escherichia coli. J Evol Biol. 26:1655–1664.
16	Harmand N, Gallet R, Jabbour-Zahab R, Martin G, Lenormand T. 2017. Fisher's geometrical model and
17	the mutational patterns of antibiotic resistance across dose gradients. <i>Evolution</i> . 71:23–37.
18	Hinz AJ, Stenzler B, Poulain AJ. 2022. Golden Gate Assembly of Aerobic and Anaerobic Microbial
19	Bioreporters. Appl Environ Microbiol. 88:e01485-21.

1	Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJV.
2	2016. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 387:176-
3	187.
4	Hopkins KL, Davies RH, Threlfall EJ. 2005. Mechanisms of quinolone resistance in Escherichia coli and
5	Salmonella: Recent developments. Int J Antimicrob Agents. 25:358–373.
6	Hughes D, Andersson DI. 2017. Evolutionary Trajectories to Antibiotic Resistance. Annu Rev Microbiol.
7	71:579–596.
8	Huseby DL, Pietsch F, Brandis G, Garoff L, Tegehall A, Hughes D. 2017. Mutation Supply and Relative
9	Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli. Mol Biol Evol.
10	34:1029–1039.
11	Jackson N, Czaplewski L, Piddock LJV. 2018. Discovery and development of new antibacterial drugs:
12	learning from experience? J Antimicrob Chemother. 73:1452-1459.
13	Johnson MS, Reddy G, Desai MM. 2023. Epistasis and evolution: recent advances and an outlook for
14	prediction BMC Biol 21:120
	prediction. Dire 200 21020.
15	Khan AI, Dinh DM, Schneider D, Lenski RE, Cooper TF. 2011. Negative Epistasis Between Beneficial
16	Mutations in an Evolving Bacterial Population. Science. 332:1193–1196.
17	Kryazhimskiy S, Rice DP, Jerison ER, Desai MM. 2014. Global epistasis makes adaptation predictable
18	despite sequence-level stochasticity. Science. 344:1519-1522.
19	Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. <i>Nat Methods</i> . 9:357–359.

1	Laube N, Mohr B, Hesse A. 2001. Laser-probe-based investigation of the evolution of particle size
2	distributions of calcium oxalate particles formed in artificial urines. J Cryst Growth. 233:367-
3	374.
4	Leale AM, Kassen R. 2018. The emergence, maintenance, and demise of diversity in a spatially variable
5	antibiotic regime. Evolution Letters. 2:134–143.
6	Lebeuf-Taylor E, McCloskey N, Bailey SF, Hinz A, Kassen R. 2019. The distribution of fitness effects
7	among synonymous mutations in a gene under directional selection. eLife. 8:e45952.
8	Lee JK, Lee YS, Park YK, Kim BS. 2005. Alterations in the GyrA and GyrB subunits of topoisomerase II
9	and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of
10	Pseudomonas aeruginosa. Int J Antimicrob Agents. 25:290–295.
11	Lennen RM, Nilsson Wallin AI, Pedersen M, Bonde M, Luo H, Herrgard MJ, Sommer MOA. 2016.
12	Transient overexpression of DNA adenine methylase enables efficient and mobile genome
13	engineering with reduced off-target effects. <i>Nucleic Acids Res.</i> 44:e36.
14	Maharjan R, Ferenci T. 2017. The fitness costs and benefits of antibiotic resistance in drug-free
15	microenvironments encountered in the human body. Environ Microbiol Rep. 9:635–641.
16	McCarthy A. 2020. Identification of Hypermutator Enterohemorrhagic Escherishia coli (EHEC) Using a
17	High Throughput Screening Method to Inform Food Safety Investigations. Available from:
18	https://repository.library.carleton.ca/concern/etds/qr46r1659
19	Melnyk AH, McCloskey N, Hinz AJ, Dettman J, Kassen R. 2017. Evolution of Cost-Free Resistance
20	under Fluctuating Drug Selection in <i>Pseudomonas aeruginosa</i> . <i>mSphere</i> . 2:e00158-17.
21	Melnyk AH, Wong A, Kassen R. 2015. The fitness costs of antibiotic resistance mutations. Evol Appl.
22	8:273–283.

1	Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L. 2009. Mechanisms accounting for
2	fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother.
3	53:235–241.
4	Nakamura S, Nakamura M, Kojima T, Yoshida H. 1989. gyrA and gyrB mutations in quinolone-resistant
5	strains of Escherichia coli. Antimicrob Agents Chemother. 33:254–255.
6	Oethinger M, Podglajen I, Kern WV, Levy SB. 1998. Overexpression of the marA or soxS Regulatory
7	Gene in Clinical Topoisomerase Mutants of Escherichia coli. Antimicrob Agents Chemother.
8	42:2089–2094.
9	Perfeito L, Sousa A, Bataillon T, Gordo I. 2014. Rates of Fitness Decline and Rebound Suggest Pervasive
10	Epistasis. Evolution. 68:150–162.
11	Pitiriga V, Vrioni G, Saroglou G, Tsakris A. 2017. The Impact of Antibiotic Stewardship Programs in
12	Combating Quinolone Resistance: A Systematic Review and Recommendations for More
13	Efficient Interventions. Adv Ther. 34:854–865.
14	Polzin S, Huber C, Eylert E, Elsenhans I, Eisenreich W, Schmidt H. 2013. Growth Media Simulating Ileal
15	and Colonic Environments Affect the Intracellular Proteome and Carbon Fluxes of
16	Enterohemorrhagic Escherichia coli O157:H7 Strain EDL933. Appl Environ Microbiol. 79:3703-
17	3715.
18	R Core Team. 2021. R: A Language and Environment for Statistical Computing. Available from:
19	https://www.R-project.org/
20	Rakowski SA, Filutowicz M. 2013. Plasmid R6K replication control. <i>Plasmid</i> . 69:231–242.
21	Rauw WM, Gomez-Raya L. 2015. Genotype by environment interaction and breeding for robustness in
22	livestock. Front Genet. 6:310.

1	Rosenberg EY, Bertenthal D, Nilles ML, Bertrand KP, Nikaido H. 2003. Bile salts and fatty acids induce
2	the expression of Escherichia coli AcrAB multidrug efflux pump through their interaction with
3	Rob regulatory protein. Mol Microbiol. 48:1609–1619.
4	Saltikov CW, Newman DK. 2003. Genetic identification of a respiratory arsenate reductase. Proc Natl
5	Acad Sci U S A. 100:10983–10988.
6 7	Sambrook J, Russell D. 2001. Molecular cloning : a laboratory manual. New York: Cold Spring Harbor Laboratory Press.
8	Sreevatsan S, Pan X, Stockbauer KE, Williams DL, Kreiswirth BN, Musser JM. 1996. Characterization of
9	rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from
10	diverse geographic localities. Antimicrob Agents Chemother. 40:1024–1026.
11	Sundqvist M, Geli P, Andersson DI, Sjölund-Karlsson M, Runehagen A, Cars H, Abelson-Storby K, Cars
12	O, Kahlmeter G. 2010. Little evidence for reversibility of trimethoprim resistance after a drastic
13	reduction in trimethoprim use. J Antimicrob Chemother. 65:350–360.
14	Szendro IG, Schenk MF, Franke J, Krug J, de Visser JAGM. 2013. Quantitative analyses of empirical
15	fitness landscapes. J Stat Mech. 2013:P01005.
16	Tang KL, Caffrey NP, Nóbrega DB, Cork SC, Ronksley PE, Barkema HW, Polachek AJ, Ganshorn H,
17	Sharma N, Kellner JD, et al. 2017. Restricting the use of antibiotics in food-producing animals
18	and its associations with antibiotic resistance in food-producing animals and human beings: a
19	systematic review and meta-analysis. Lancet Planet Health. 1:e316–e327.
20	Trindade S, Sousa A, Gordo I. 2012. Antibiotic resistance and stress in the light of Fisher's model.
21	Evolution. 66:3815–3824.

<ul> <li>Acquisition of Multidrug Resistance. <i>PLOS Genet.</i> 5:e1000578.</li> <li>Ullmann A. 2009. <i>Escherichia coli</i> Lactose Operon. In: Encyclopedia of Life Sciences (ELS). Ayaila</li> <li>from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470015902.a0000849.pub2</li> <li>Veldman KT, Mevius DJ. 2018. Monitoring of Antimicrobial Resistance and Antibiotic Usage in</li> <li>Animals in the Netherlands in 2017 (Maran 2018). Available from:</li> <li>https://www.wur.nl/nl/show/Maran-rapport-2018.htm</li> <li>Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, de Anta TJ. 1994. Association between dout</li> <li>mutation in <i>gyrA</i> gene of ciprofloxacin-resistant clinical isolates of <i>Escherichia coli</i> and MI</li> <li><i>Antimicrob Agents Chemother</i> 38:2477–2479.</li> <li>Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a</li> <li>genetic background shape the filness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i></li> <li><i>Soc B</i>. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me</li> <li>analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mor</li> <li>FB-G Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-</li> <li>5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	1	Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I. 2009. Positive Epistasis Drives the
<ul> <li>Ullmann A. 2009. <i>Escherichia coli</i> Lactose Operon. In: Encyclopedia of Life Sciences (ELS). Availa</li> <li>from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470015902.a0000849.pub2</li> <li>Veldman KT, Mevius DJ. 2018. Monitoring of Antimicrobial Resistance and Antibiotic Usage in</li> <li>Animals in the Netherlands in 2017 (Maran 2018). Available from:</li> <li>https://www.wur.nl/al/show/Maran-rapport-2018.htm</li> <li>Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, de Anta TJ. 1994. Association between dout</li> <li>mutation in <i>gyrA</i> gene of ciprofloxacin-resistant clinical isolates of <i>Escherichia coli</i> and MI</li> <li><i>Antimicrob Agents Chemother</i> 38:2477–2479.</li> <li>Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a</li> <li>genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i></li> <li><i>Soc B</i>. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me</li> <li>analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod</li> <li>FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-</li> <li>5052.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	2	Acquisition of Multidrug Resistance. PLOS Genet. 5:e1000578.
<ul> <li>from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470015902.a0000849.pub2</li> <li>Veldman KT, Mevius DJ. 2018. Monitoring of Antimicrobial Resistance and Antibiotic Usage in</li> <li>Animals in the Netherlands in 2017 (Maran 2018). Available from:</li> <li>https://www.wur.nl/nl/show/Maran-rapport-2018.htm</li> <li>Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, de Anta TJ. 1994. Association between dout</li> <li>mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of <i>Escherichia coli</i> and MI</li> <li><i>Antimicrob Agents Chemother</i> 38:2477–2479.</li> <li>Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a</li> <li>genetic background shape the filmess effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i></li> <li><i>Soc B</i>. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the filmess costs of antimicrobial resistance: a me</li> <li>analysis approach. <i>Evol Appl.</i> 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mor</li> <li>FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the film</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A.</i> 113:50</li> <li>5052.</li> <li>Word Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	3	Ullmann A. 2009. Escherichia coli Lactose Operon. In: Encyclopedia of Life Sciences (ELS). Available
<ul> <li>5 Veldman KT, Mevius DJ. 2018. Monitoring of Antimicrobial Resistance and Antibiotic Usage in</li> <li>6 Animals in the Netherlands in 2017 (Maran 2018). Available from:</li> <li>7 https://www.wur.nl/nl/show/Maran-rapport-2018.htm</li> <li>8 Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, de Anta TJ. 1994. Association between dout</li> <li>9 mutation in <i>gyrA</i> gene of ciprofloxacin-resistant clinical isolates of <i>Escherichia coli</i> and MI</li> <li>10 <i>Antimicrob Agents Chemother</i> 38:2477–2479.</li> <li>11 Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a</li> <li>12 genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i></li> <li>13 <i>Soc B</i>. 283:20160151.</li> <li>14 Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me</li> <li>15 analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>16 Wang Y, Diaz Arenas C, Stocbel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Moo</li> <li>17 FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm</li> <li>18 of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-</li> <li>19 5052.</li> <li>20 Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>21 World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>22 http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	4	from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470015902.a0000849.pub2
<ul> <li>Animals in the Netherlands in 2017 (Maran 2018). Available from: https://www.wur.nl/nl/show/Maran-rapport-2018.htm</li> <li>Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, de Anta TJ. 1994. Association between dout mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of <i>Escherichia coli</i> and MI <i>Antimicrob Agents Chemother</i> 38:2477–2479.</li> <li>Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i> <i>Soc B</i>. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mor FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50- 5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	5	Veldman KT, Mevius DJ. 2018. Monitoring of Antimicrobial Resistance and Antibiotic Usage in
<ul> <li>https://www.wur.nl/nl/show/Maran-rapport-2018.htm</li> <li>Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, de Anta TJ. 1994. Association between dout</li> <li>mutation in <i>gyrA</i> gene of ciprofloxacin-resistant clinical isolates of <i>Escherichia coli</i> and MI</li> <li><i>Antimicrob Agents Chemother</i> 38:2477–2479.</li> <li>Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a</li> <li>genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i></li> <li><i>Soc B</i>. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me</li> <li>analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod</li> <li>FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-</li> <li>5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	6	Animals in the Netherlands in 2017 (Maran 2018). Available from:
<ul> <li>Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, de Anta TJ. 1994. Association between dout mutation in <i>gyrA</i> gene of ciprofloxacin-resistant clinical isolates of <i>Escherichia coli</i> and MI <i>Antimicrob Agents Chemother</i> 38:2477–2479.</li> <li>Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i> <i>Soc B</i>. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50- 5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Available fro</i> http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	7	https://www.wur.nl/nl/show/Maran-rapport-2018.htm
<ul> <li>9 mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of <i>Escherichia coli</i> and MI</li> <li>10 Antimicrob Agents Chemother 38:2477–2479.</li> <li>11 Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a</li> <li>genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i></li> <li>13 <i>Soc B</i>. 283:20160151.</li> <li>14 Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me</li> <li>analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>16 Wang Y, Díaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod</li> <li>17 FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-</li> <li>5052.</li> <li>20 Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>21 World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	8	Vila J, Ruiz J, Marco F, Barcelo A, Goñi P, Giralt E, de Anta TJ. 1994. Association between double
<ul> <li>Antimicrob Agents Chemother 38:2477–2479.</li> <li>Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i> <i>Soc B</i>. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50- 5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	9	mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs.
<ul> <li>Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations a</li> <li>genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i></li> <li><i>Soc B.</i> 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me</li> <li>analysis approach. <i>Evol Appl.</i> 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod</li> <li>FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A.</i> 113:50-</li> <li>5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol.</i> 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	10	Antimicrob Agents Chemother 38:2477–2479.
<ul> <li>genetic background shape the fitness effect of resistance across species of <i>Pseudomonas</i>. <i>Pro</i></li> <li><i>Soc B</i>. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me</li> <li>analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod</li> <li>FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:504</li> <li>5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	11	Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance mutations and
<ul> <li>Soc B. 283:20160151.</li> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a meta analysis approach. <i>Evol Appl.</i> 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	12	genetic background shape the fitness effect of resistance across species of Pseudomonas. Proc R
<ul> <li>Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a me analysis approach. <i>Evol Appl</i>. 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitn of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50- 5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	13	Soc B. 283:20160151.
<ul> <li>analysis approach. <i>Evol Appl.</i> 8:284–295.</li> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mod</li> <li>FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitn</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-</li> <li>5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	14	Vogwill T, MacLean RC. 2015. The genetic basis of the fitness costs of antimicrobial resistance: a meta-
<ul> <li>Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Mor</li> <li>FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-</li> <li>5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	15	analysis approach. Evol Appl. 8:284–295.
<ul> <li>FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitm</li> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-</li> <li>5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol.</i> 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	16	Wang Y, Diaz Arenas C, Stoebel DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Moore
<ul> <li>of recipients than by their ecological or genetic relatedness. <i>Proc Natl Acad Sci U S A</i>. 113:50-5052.</li> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	17	FB-G, Cooper VS, et al. 2016. Benefit of transferred mutations is better predicted by the fitness
<ul> <li>19 5052.</li> <li>20 Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>21 World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro 22 http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	18	of recipients than by their ecological or genetic relatedness. Proc Natl Acad Sci USA. 113:5047-
<ul> <li>Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. <i>Front Microbiol</i>. 8:246.</li> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	19	5052.
<ul> <li>World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available fro</li> <li>http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</li> </ul>	20	Wong A. 2017. Epistasis and the Evolution of Antimicrobial Resistance. Front Microbiol. 8:246.
22 http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/	21	World Health Organization. 2015. Global Action Plan on Antimicrobial Resistance. Available from:
	22	http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/

1	Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PRS, Walkty A,
2	Karlowsky JA, Schweizer F, et al. 2013. Antimicrobial susceptibility of 22746 pathogens from
3	Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother. 68 Suppl
4	1:i7-22.

5

# 6 Figure Legends

7

Fig 1. Library of E. coli isolates with introduced AMR mutations. The gene and specific 8 amino acid change of the 7 introduced mutations are indicated. The mutations confer resistance 9 to three antibiotic classes and alter the indicated cellular targets. The 12 E. coli genetic 10 backgrounds include a common laboratory strain (MG1655) and 11 clinical isolates collected 11 from patients in Canadian hospitals. 67 of the 84 potential mutation-by-genotype combinations 12 were successfully constructed. 13 combinations were not attempted due to elevated resistance of 13 the ancestor to the respective antibiotic (Resistant), and four combinations were unsuccessfully 14 15 introduced (NA), PB10, PB13, and PB15 already harbored both S83L and D87N mutations in gyrA, likely contributing to elevated fluoroquinolone resistance. No other isolates carried known 16 resistance mutations in the genes under investigation. 17

18

#### 19 Fig 2. Mutations introduced in different genetic backgrounds consistently increase

20 resistance to target antibiotics. Median fold-changes in antibiotic susceptibility [log2 (MIC<sub>mutant</sub>

21 / MIC<sub>ancestor</sub>)] are plotted for mutants with introduced (A) fluoroquinolone, (B) rifampicin, and

- 22 (C) aminoglycoside resistance mutations. MICs were determined for three antibiotics (one target
- and two non-target) in triplicate. Individual points within each category represent different

genetic backgrounds with the same introduced mutation. Each of the mutations significantly
increased resistance to target antibiotics across genetic backgrounds (multiple comparison t-test
with Bonferroni correction; p<sub>adj</sub><0.05) with no significant effects on susceptibility to off-target</li>
antibiotics. The collateral streptomycin sensitivity observed for the RpoB (H526Y) mutants was
not significant when adjusting for multiple comparisons (p<sub>adj</sub>=0.54).

6

Fig 3. AMR mutations exhibit wide variation in fitness effects across genetic backgrounds. 7 8 The fitness effects of AMR mutations were determined in four antibiotic-free environments: LB, M9-Glucose, synthetic urine medium, and synthetic colon medium. The data are grouped by 9 mutation and environment, with individual points indicating fitness effects measured in different 10 genetic backgrounds. The boxplots summarize the distributions of fitness effects (median, first 11 and third quartiles, and nonoutlier minimum and maximum values). Additional fitness effect 12 information including genetic background identities, relative fitness values, and significance 13 14 levels is provided in supplementary fig. S3.

15

Fig 4. Fitness effects variance and epistasis between AMR mutations and genetic
backgrounds differed between environments. The overall mean (A) and variance (B) of
fitness effects of all mutation-genetic background combinations (67 mutants) were determined in
each growth environment. Global epistasis (C) was estimated as gamma epistasis. Analysis of
the amount and proportion of epistasis types (i.e., magnitude vs. sign epistasis) underlying the
epistasis measure are found in supplementary fig. S4.

Fig 5. Genotype by environment interactions explain most of the variation in fitness effects
for each AMR mutation. The experimental fitness effects data for each mutation was fit to a
random effects model to determine the amount (A) and proportion (B) of variance explained by
Genotype (i.e., the genetic background), Environment, and the Genotype by Environment
interaction. Reaction norm plots showing the responses of specific genotypes in each
environment are found in supplementary fig. S5.

Fig 6. A Rough Mount Fuji genotype-fitness model only partially reproduces the

7

8

#### experimental fitness effect statistics. (A) Log-likelihood surfaces for the mean of fitness 9 effects, the variance of fitness effects, and the gamma epistasis parameter of the experimental 10 data under a RMF model. x-axis represents the variance of the additive component ( $\sigma_a$ ) and y-11 axis the variance of the epistatic contribution ( $\sigma_b$ ). Each row shows log-likelihood surfaces for 12 single environments and the last row for the conjugation of the four environments. The red dot 13 represents an analytical estimate of the best parameters based on the mean values of the 14 experimental data statistics only. The mean of the additive fitness effects (model parameter $\mu_a$ ) 15 16 was fixed to the experimentally measured mean. (B) The RMF model cannot simultaneously capture the distribution of the variance of fitness effects and the epistasis for the four 17 environments. The figure shows the distribution of the mean of fitness effects, the variance of 18 19 fitness effects, and the gamma parameter under a RMF model. The top row represents a RMF 20 landscape with parameters optimized to describe the variance of fitness effects and the bottom row optimized to describe the gamma parameter. The vertical colored lines represent the 21 experimental value for each environment, with the dashed lines delimiting one standard 22

deviation. The blue corresponds to LB, the orange to M9-Glucose, the green to synthetic urine
 medium, and the red to synthetic colon medium.

3

#### Fig 7. Fitness effects of the AMR mutations correlate weakly between pairs of 4 environments. We determined the correlation of fitness effects of mutations when measured in 5 different environments. For each environmental pair, the correlation coefficients (Pearson's r) 6 are plotted when including all mutants in the library (A), or when grouped by introduced 7 8 mutation (B). Error bars indicate a one standard deviation range and horizontal lines indicate the mean of the correlation coefficients for all 6 comparisons. Correlation scatterplots, correlation 9 coefficients, and significance values are provided in supplementary figs. S6 and S7. 10 11 Fig 8. The fitness effects are not explained by differences in fitness or phylogenetic 12 relatedness of the ancestral genetic backgrounds. The results of all pairwise comparisons 13 14 between the 67 AMR mutants are shown, with difference in fitness effects plotted against difference in background fitness (A) or phylogenetic distance (B) for each comparison. Genetic 15 background fitness was measured in head-to-head competitions between the twelve E. coli 16 ancestors and a common competitor in each of the four growth environments (supplementary fig. 17 S8A). Phylogenetic distance was estimated from a phylogeny based on whole genome 18 19 alignments of the E. coli isolates (supplementary fig. S8B). The correlation lines and 95% 20 confidence intervals are depicted for all mutants tested in each environment. Supplementary figs. 21 S9 and S10 show the correlations grouped by mutation. 22



#### **Resistance mutations**



182x73 mm (x DPI)



